This information was published on 2025-09-17T11:38:30 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2457763 (IR 1794106) |
| (220) |
14 Feb 2024
|
| (300) |
US, 20 Oct 2023, 98232780
|
| (500) |
Provisions of paragraph 44(3)(b) and/or Reg 4.15A(3)(b) applied.
|
| (511) (510) |
Class 40
Biomanufacturing for others, namely, manufacturing of pharmaceuticals and of viral vectors and gene therapy vectors; custom manufacturing services of ex vivo, lentiviral stable cell lines; custom manufacturing services of lentiviral vectors by transient transfection; biomanufacturing of viral vectors and gene therapy vectors; biomanufacturing services of cell lines and cells; biomanufacturing of biological preparations. Class 42 Scientific, pharmaceutical and medical research and development; biological research; laboratory services in connection with viral vectors and gene therapy vectors; scientific, pharmaceutical, and medical research platform services featuring bioproduction, regulatory pathway services, accessory proteins and alternative envelope proteins. Class 45 Regulatory and process pathway consulting for clinical manufacturing. |
| (540) | CYTEGRITY |
| (550) | Word |
| (730) |
CSL Behring Gene Therapy, Inc.
|
| (750) |
Davies Collison Cave Pty Ltd
|
Find out more about publications on the About page.